Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H16N2O2.ClH.2H2O |
| Molecular Weight | 316.781 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.Cl.O=C1NC=CC2=C1C=CC(OC3CCNCC3)=C2
InChI
InChIKey=NOAORRYIRXPUJV-UHFFFAOYSA-N
InChI=1S/C14H16N2O2.ClH.2H2O/c17-14-13-2-1-12(9-10(13)3-8-16-14)18-11-4-6-15-7-5-11;;;/h1-3,8-9,11,15H,4-7H2,(H,16,17);1H;2*1H2
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H16N2O2 |
| Molecular Weight | 244.289 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
SAR407899 is a potent, ATP-competitive Rho kinase inhibitor. It antihypertensive action in animals. Sanofi is developing SAR 407899 for the treatment of microvascular angina (Syndrome X). It was previously being developed in clinical trials for the treatment of diabetic neuropathies, diabetic nephropathies, erectile dysfunction, pulmonary hypertension, hypertension and kidney disorders, but development was discontinued for those indications.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037 |
36.0 nM [Ki] | ||
Target ID: CHEMBL3231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037 |
276.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator​
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [IC50 21.3174 uM] | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no |
PubMed
| Title | Date | PubMed |
|---|---|---|
| End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899. | 2015-01-26 |
|
| Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease. | 2013 |
|
| The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. | 2012-05 |
|
| Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. | 2012-03-23 |
|
| Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. | 2009-09 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037
Curator's Comment: SAR407899 is in clinical trials but dosage and regimen are unknown. http://adisinsight.springer.com/drugs/800026023
rats: (0.01 to 0.30 mg/kg IV), (orally at 1, 3, 10, and 30 mg/kg)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19597037
SAR407899 effectively inhibited THP-1 migration with an IC50 of 2.5 uM
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:25:13 GMT 2025
by
admin
on
Mon Mar 31 23:25:13 GMT 2025
|
| Record UNII |
14I47Q05LE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1417611-24-5
Created by
admin on Mon Mar 31 23:25:13 GMT 2025 , Edited by admin on Mon Mar 31 23:25:13 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
14I47Q05LE
Created by
admin on Mon Mar 31 23:25:13 GMT 2025 , Edited by admin on Mon Mar 31 23:25:13 GMT 2025
|
PRIMARY | |||
|
86675574
Created by
admin on Mon Mar 31 23:25:13 GMT 2025 , Edited by admin on Mon Mar 31 23:25:13 GMT 2025
|
PRIMARY | |||
|
1417424-23-7
Created by
admin on Mon Mar 31 23:25:13 GMT 2025 , Edited by admin on Mon Mar 31 23:25:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|